Future work aimed at targeting the IRF4 addiction in MM may be more effective if re‐focused on direct inhibition or degradation of IRF4, which could be then used in synergistic combination to address relapsed or refractory cases of MM for which presently limited choices exist. Here, IRF4 is linked to Miyoshi myopathy.